Intercell appoints Staph Leavenworth Bakali as CBO
This article was originally published in Scrip
Executive Summary
Staph Leavenworth Bakali has been named chief business officer of Intercell, an Austria-based biotech company developing vaccines for the prevention and treatment of infectious diseases. Mr Leavenworth Bakali has more than 20 years' vaccine industry experience, having most recently served as CEO of the US-based biotech vaccine company Genocea Biosciences. He has also worked as chief operating officer for ID Biomedical and PowderJect, which were acquired by GlaxoSmithKline and Chiron, respectively.